Olimesta Combi (Olmesartan Medoxomil, Hydrochlorothiazide)

Olimesta Combi combines two antihypertensive agents that act on the renin‑angiotensin‑aldosterone system to lower blood pressure.

• Hypertension: provides effective blood‑pressure reduction in patients who need combined ARB and thiazide therapy.
• Resistant hypertension: adds diuretic effect to improve control when monotherapy is insufficient.
• Edema associated with hypertension: helps reduce fluid retention through the diuretic component.

• Olmesartan medoxomil blocks the binding of angiotensin II to the AT1 receptor on vascular smooth‑muscle and adrenal cells, preventing vasoconstriction and aldosterone release. Hydrochlorothiazide inhibits sodium‑chloride reabsorption in the distal convoluted tubule, promoting diuresis and further lowering circulating volume and peripheral resistance.

Adverse reactions may range from mild to serious and should be monitored during therapy.

Common Side Effects

• Dizziness or light‑headedness
• Headache
• Fatigue
• Increased urination
• Electrolyte disturbances (e.g., low potassium)
• Mild gastrointestinal discomfort

Serious or Rare Side Effects

• Severe hypotension
• Acute kidney injury
• Hyperkalemia
• Angio‑edema
• Severe electrolyte imbalance
• Allergic skin reactions (e.g., Stevens‑Johnson syndrome)

Before initiating therapy, clinicians should evaluate patient history and monitor relevant parameters.

• Renal function: assess baseline creatinine and eGFR, adjust if impaired.
• Electrolytes: monitor potassium and sodium levels regularly.
• Pregnancy: contraindicated in the second and third trimesters; avoid use.
• Concomitant drugs: review for potential interactions, especially other antihypertensives.
• Orthostatic hypotension: advise patients to rise slowly to reduce fall risk.
• Store below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Olimesta Combi may interact with several drug classes; careful review is essential.

Major Interactions (Avoid)

• Aliskiren (in diabetic patients): risk of renal dysfunction and hyperkalemia.
• Potassium‑sparing diuretics or supplements: may cause dangerous hyperkalemia.
• Lithium: increased lithium levels and toxicity risk.

Moderate Interactions (Monitor Closely)

• Non‑steroidal anti‑inflammatory drugs (NSAIDs): may blunt antihypertensive effect and affect renal function.
• ACE inhibitors or other ARBs: additive blood‑pressure lowering, risk of hypotension.
• Antidiabetic agents: may enhance glucose‑lowering effect, requiring dose adjustment.